Strengths, Weakness, Opportunities, Threats, SWOT analysis of USA & UK markets

1. Bhukya Balaji
MSN labs
Intern

2. Strengths
• 55PCTs filed, 45published
• 137Indian Patents filed, 82published
• The MSN R&D Center includes 42 labs
& 600 scientists.
• Increased demand and ageing population as a whole.
• The wide range of Products
• 200 APIs
• 120 formulations
• 35 therapy areas
Filing of DMFs
source: http://www.msnlabs.com/

3. Weakness
• There is no single portal contains of all pharma producers and their products.
• Wholesalers buy and sell drugs in response to market demand, repeatedly
repackaging products.
• Raising the minimum standards for drug build momentum for increased control of
the drug market in low- and middle-income countries.
• Price regulations.
• Rooted Mobile Devices leaking client application IDs and shared secrets.
• Using the HTTP Malicious Patterns Detection Policy
• Transparency in supply chain
• Regulatory issues

4. Opportunities
United states spending 17-18% of total GDP on healthcare

5. Source: http://info.evaluategroup.com/rs/607-YGS-364/images/Evaluate-European-Drug-Forecasts-Infographic-IG.pdf

7. source: https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-2017-health-care-outlook-
infographic.pdf

8. Threats
• Competition from developing countries is increasing.
• R&D infrastructure and investment are under-
developed.
• Transport infrastructure and storage facilities for
temperature-sensitive drugs are not readily available.
• Rejection by regulatory bodies
• Drug Pricing control methods
• Product patent regime poses serious challenge
• Lowering of tariff protection has increased
competition in domestic markets
• Mergers and acquisitions by foreign companies
particularly multinational corporations
https://www.owler.com/company/msnlabs